Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified January 2015 by University of Michigan Cancer Center
Sponsor:
Collaborators:
GlaxoSmithKline
Gilead Sciences
Information provided by (Responsible Party):
University of Michigan Cancer Center
ClinicalTrials.gov Identifier:
NCT01528865
First received: January 12, 2012
Last updated: January 7, 2015
Last verified: January 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: August 2016
  Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)